http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#Head http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#assertion http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#provenance http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#pubinfo http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#assertion http://purl.obolibrary.org/obo/MONDO_0024612 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/MONDO_0024612 http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/DRUGBANK:DB01267 http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#association http://www.w3.org/2000/01/rdf-schema#label Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12) http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#association https://w3id.org/biolink/vocab/publications https://pubmed.ncbi.nlm.nih.gov/31096228 http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/OffLabelIndication https://identifiers.org/DRUGBANK:DB01267 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#provenance http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#assertion http://www.w3.org/ns/prov#generatedAtTime 2021-08-24T15:53:47.29208 http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#pubinfo http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#sig http://purl.org/nanopub/x/hasSignature S36lxqMhE/il6hZ0x3opIf+BSGkgmrLS42CchAvMGjt03GhGQT20XdwHEBLps4EIevPEFYR3JCJttJowJ3HtWv4hSQ5sLxtGzcLW+7AD86Mrp/G3xGClqtMyQmf0MU7glLc83g8n8nenTaQOX37aaSuUPH+I3cZQJ1cSqTfX5ss= http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps http://purl.org/dc/terms/created 2021-09-13T13:11:54.555+02:00 http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps http://purl.org/dc/terms/creator https://orcid.org/0000-0002-7641-6446 http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps http://purl.org/nanopub/x/supersedes http://purl.org/np/RA5i91jVBRKHpwDOPIiWGzt3c3Rs8wAqKRXxOYhegMxOI http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps http://www.w3.org/ns/prov#generatedAtTime 2021-08-24T15:53:47.29208 http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-7641-6446 http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RAcm8OurwUk15WOgBM9wySo-T3a5h6as4K8YR5MBrrxUc http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RA2vCBXZf-icEcVRGhulJXugTGxpsV5yVr9yqCI1bQh4A http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAjpBMlw3owYhJUBo3DtsuDlXsNAJ8cnGeWAutDVjuAuI http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY